Marcus M. Schittenhelm

Author

Also Known As

M M Schittenhelm, M Schittenhelm, M. M. Schittenhelm, M. Schittenhelm, M.M. Schittenhelm, Marcus M Schittenhelm, Marcus M. Schittenhelm, Marcus Matthias Schittenhelm, Marcus Schittenhelm

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

University of Tübingen University Children's Hospital Tübingen Oregon Health & Science University University Hospital Ulm University Medical Center Hamburg-Eppendorf

About

Marcus M. Schittenhelm is an author at University of Tübingen specializing in medicine, systems biology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	406
2	Cell Biology	2	2	117
3	Engineering	1	1	195
4	Immunology	1	1	94
5	Molecular Genetics	1	1	195

Marcus M. Schittenhelm

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies Marcus M. Schittenhelm, Sharon Shiraga, Arin Schroeder, Cancer Research	2006	466
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia Jan Krönke, Lars Bullinger, Veronica Teleanu, Blood	2013	263
Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles Stefan Fröhling, Claudia Scholl, Ross L. Levine, Cancer Cell Genetic AnalysisFunctional AssessmentAllelic VariantEngineeringGenetic Disorder	2007	195
Functional response of leukaemic blasts to stromal cell‐derived factor‐1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia Robert Möhle, Marcus M. Schittenhelm, Cornelia Failenschmid, British Journal of Haematology	2000	145
Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro Sandra Koch, Frank Mayer, Friedemann Honecker, British Journal of Cancer	2003	123
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms Kerstin Maria Kampa-Schittenhelm, Michael C. Heinrich, Figen Akmut, Molecular Cancer	2013	121
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells Kevin Yee, Marcus M. Schittenhelm, Anne-Marie O'Farrell, Blood	2004	120
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating <i>FLT3</i> mutations Walter Fiedler, Sabine Käyser, Maxim Kebenko, British Journal of Haematology	2015	104
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC) Christian Kollmannsberger, Marcus M. Schittenhelm, Friedemann Honecker, Annals of Oncology MedicineImmunologyPathologyBronchial NeoplasmCancer Treatment	2006	94
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial Michael Lübbert, Olga Grishina, Claudia Schmoor, Journal of Clinical Oncology	2019	88

Page 1